Barinthus Biotherapeutics PLC
BRNS0.739USD
+0.008+1.04%
收盤 12/19, 16:00（美東）報價延遲15分鐘
30.17M總市值
虧損本益比TTM
關於 Barinthus Biotherapeutics PLC 公司
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Barinthus Biotherapeutics PLC簡介
公司代碼BRNS
公司名稱Barinthus Biotherapeutics PLC
上市日期Apr 30, 2021
CEOEnright (William J)
員工數量105
證券類型Depository Receipt
年結日Apr 30
公司地址Unit 6-10, Zeus Building, Rutherford Avenue
城市DIDCOT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編OX11 0DF
電話441865818808
網址https://www.barinthusbio.com/
公司代碼BRNS
上市日期Apr 30, 2021
CEOEnright (William J)
Barinthus Biotherapeutics PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Oxford Science Enterprises PLC
21.55%
M&G Investment Management Ltd.
12.73%
Cawood (Frank Wayne)
8.29%
Alphabet, Inc.
3.71%
HSG Holding Ltd.
3.48%
其他
50.25%
持股股東
持股股東
佔比
Oxford Science Enterprises PLC
21.55%
M&G Investment Management Ltd.
12.73%
Cawood (Frank Wayne)
8.29%
Alphabet, Inc.
3.71%
HSG Holding Ltd.
3.48%
其他
50.25%
股東類型
持股股東
佔比
Venture Capital
25.29%
Investment Advisor
17.92%
Individual Investor
13.37%
Endowment Fund
0.30%
Investment Advisor/Hedge Fund
0.29%
Hedge Fund
0.16%
Research Firm
0.05%
其他
42.62%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
31
17.97M
45.74%
--
2025Q3
32
17.97M
45.74%
-38.01K
2025Q2
30
18.01M
46.38%
+65.89K
2025Q1
30
18.02M
46.62%
-782.82K
2024Q4
29
18.00M
46.88%
-589.55K
2024Q3
29
18.59M
48.15%
-228.24K
2024Q2
30
18.82M
49.02%
+214.04K
2024Q1
29
18.61M
49.21%
-561.80K
2023Q4
34
18.63M
49.81%
+1.21K
2023Q3
36
18.62M
50.13%
-140.49K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Oxford Science Enterprises PLC
8.80M
21.55%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.73%
--
--
Jun 30, 2025
Cawood (Frank Wayne)
3.38M
8.29%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.71%
--
--
Jun 30, 2025
HSG Holding Ltd.
1.42M
3.48%
--
--
Jun 30, 2025
Enright (William)
1.24M
3.05%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.57%
--
--
Jun 30, 2025
Lynn (Geoffrey)
638.44K
1.56%
+638.44K
--
Dec 17, 2024
Johns Hopkins University
122.24K
0.3%
--
--
Jun 30, 2025
Robert W. Baird & Co. Inc.
192.46K
0.47%
+100.00K
+108.15%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Barinthus Biotherapeutics PLC的前五大股東是誰？
Barinthus Biotherapeutics PLC的前五大股東如下：
Oxford Science Enterprises PLC持有股份：8.80M佔總股份比例：21.55%。
M&G Investment Management Ltd.持有股份：5.20M佔總股份比例：12.73%。
Cawood (Frank Wayne)持有股份：3.38M佔總股份比例：8.29%。
Alphabet, Inc.持有股份：1.51M佔總股份比例：3.71%。
HSG Holding Ltd.持有股份：1.42M佔總股份比例：3.48%。
Oxford Science Enterprises PLC持有股份：8.80M佔總股份比例：21.55%。
M&G Investment Management Ltd.持有股份：5.20M佔總股份比例：12.73%。
Cawood (Frank Wayne)持有股份：3.38M佔總股份比例：8.29%。
Alphabet, Inc.持有股份：1.51M佔總股份比例：3.71%。
HSG Holding Ltd.持有股份：1.42M佔總股份比例：3.48%。
Barinthus Biotherapeutics PLC的前三大股東類型是什麼？
Barinthus Biotherapeutics PLC 的前三大股東類型分別是：
Oxford Science Enterprises PLC
M&G Investment Management Ltd.
Cawood (Frank Wayne)
Oxford Science Enterprises PLC
M&G Investment Management Ltd.
Cawood (Frank Wayne)
有多少機構持有Barinthus Biotherapeutics PLC(BRNS)的股份？
截至2025Q4，共有31家機構持有Barinthus Biotherapeutics PLC的股份，合計持有的股份價值約為17.97M，占公司總股份的45.74% 。與2025Q3相比，機構持股有所增加，增幅為-0.00%。
哪個業務部門對Barinthus Biotherapeutics PLC的收入貢獻最大？
在--，--業務部門對Barinthus Biotherapeutics PLC的收入貢獻最大，創收--，占總收入的--% 。
